EHS
EHS

STAT Plus: Novartis is the latest big drug maker to exit antibiotic research

Amid rising concern over drug-resistant superbugs, Novartis (NVS) is ending research into antibiotics and antivirals because these programs are not a “long-term strategic fit.”

As a result, the company will eliminate 140 jobs from the San Francisco Bay area, where the work is based, although a Novartis spokesman noted the company will continue to research tropical diseases, such as malaria. And he added that the company’s Sandoz generic unit continues to manufacture and supply many such medicines.

Continue to STAT Plus to read the full story…

EHS
Back to top button